Axoft, a pioneering neurotechnology company, today announced the closing of an oversubscribed $55 million Series A funding round.

The round was led by C.P. Group Innovation and joined by Alumni Ventures, the Stanford President’s Venture Fund, Hillhouse Investment, and Gaorong Ventures.

The new capital brings Axoft’s total funding to more than $60 million.

Axoft is developing next-generation implantable brain-computer interfaces (iBCIs) using Fleuron™, a proprietary material engineered to be 10,000 times softer than conventional rigid neural implants.

By closely mimicking the mechanical softness of brain tissue, the technology significantly reduces inflammation, scarring, and long-term tissue damage, key obstacles that have slowed widespread clinical adoption of BCIs.

“The brain is incredibly soft,” said Paul Le Floch, CEO and co-founder of Axoft.

“Our implants are designed to move with the brain instead of against it, delivering superior biocompatibility and stable, high-fidelity signals over years rather than months.”

Proceeds from the round will fund the expansion of global clinical trials, advance U.S. FDA regulatory clearance, and support the construction of a GMP manufacturing facility to scale production.

The company has already successfully implanted its devices in 11 patients, including recent high-fidelity brain-signal decoding trials conducted in China.

In a competitive BCI landscape, Axoft is differentiating itself through a materials-first approach that prioritizes long-term tissue integration over electrode count or wireless features.

The technology holds strong potential for restoring function in patients with paralysis, stroke, neurodegenerative diseases, and disorders of consciousness.

“This funding validates our core thesis that biocompatibility is the true bottleneck in neurotech,” added Le Floch.

“We are now positioned to move from early clinical success to meaningful patient impact at scale.”

Founded in 2021 by a team of Harvard and MIT scientists, Axoft is headquartered in Cambridge, Massachusetts.

The latest raise reflects continued strong investor appetite for deep-tech breakthroughs in neurological medicine and human augmentation.